Cardiac Imaging Methods for Chemotherapy-related Cardiotoxicity Screening and Related Radiation Exposure: Current Practice and Trends

Kolla, Bhaskar; Roy, Samit S.; Duval, Sue; Weisdorf, Daniel J.; Valeti, Uma; Blaes, Anne

doi:10.21873/anticanres.11584

Cited by 10 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results may be due to increased knowledge of patients and physicians about radiation risks associated with serial radionuclide ventriculography scans. Moreover, the findings of serial radionuclide ventriculography are similar to the findings of echocardiography and cardiac magnetic resonance imaging [53].…”

Section: Nuclear Cardiac Imaging In Cardio-oncologysupporting

confidence: 71%

State-of-the-art modalities in cardio-oncology: insight from a nuclear medicine approach

et al. 2021

View full text Add to dashboard Cite

Cancer and cardiovascular disease are the most significant causes of morbidity and mortality worldwide. Although the cancer survival rate has increased due to improved treatment approaches, especially targeted therapy, some side effects such as cardiotoxicity decrease the efficiency of the clinical outcome. Radiation therapy and chemotherapy have a long-established history of potential cardiotoxic effects. A new multi-disciplinary and translational field known as cardio-oncology has been developed for the identification, prevention, and treatment of cardiovascular dysfunctions associated with cancer treatment approaches. One of the important tools for detecting and monitoring cardiotoxic effects is non-invasive nuclear cardiac imaging techniques. Cardiac nuclear imaging modalities especially recent findings positron emission tomography (PET) tracers have a quintessential role in the early detection of cardiovascular disorders. Moreover, comprehensive studies are required to investigate novel nuclear medicine treatment approaches such as peptide receptor radionuclide therapy (PRRT), fibroblast activation protein (FAP), and chemokine receptor (CXCR) targeting probes for possible cardiac side effects that play important roles in the treatment of malignancies.

show abstract

Section: Nuclear Cardiac Imaging In Cardio-oncologysupporting

confidence: 71%

State-of-the-art modalities in cardio-oncology: insight from a nuclear medicine approach

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Multigated acquisition (MUGA) scanning was once a commonly used method for serial evaluation of cardiotoxicity. Despite low inter-and intra-observer variability, such methodology may be rendered obsolete in modern times due to low sensitivity to subtle changes and radiation exposure [27] (Table 1).…”

Section: Volumetric Assessment and Cmrmentioning

confidence: 99%

Herceptin-Mediated Cardiotoxicity: Assessment by Cardiovascular Magnetic Resonance

Jin

Liu

Hothi

2022

Cardiology Research and Practice

View full text Add to dashboard Cite

Herceptin (trastuzumab) is a recombinant, humanized, monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2) and is used in the treatment of HER2-positive breast and gastric cancers. However, it carries a risk of cardiotoxicity, manifesting as left ventricular (LV) systolic dysfunction, conventionally assessed for by transthoracic echocardiography. Clinical surveillance of cardiac function and discontinuation of trastuzumab at an early stage of LV systolic dysfunction allow for the timely initiation of heart failure drug therapies that can result in the rapid recovery of cardiac function in most patients. Often considered the reference standard for the noninvasive assessment of cardiac volume and function, cardiac magnetic resonance (CMR) imaging has superior reproducibility and accuracy compared to other noninvasive imaging modalities. However, due to limited availability, it is not routinely used in the serial assessment of cardiac function in patients receiving trastuzumab. In this article, we review the diagnostic and prognostic role of CMR in trastuzumab-mediated cardiotoxicity.

show abstract

“…In addition, MUGA is rarely used for follow-up surveillance of LVEF due to ionizing radiation exposure, an inability to provide morphological and functional information, and an inability to assess pericardial and valvular diseases [ 53 ]. A cross-sectional study showed that the usage of MUGA decreased from 30.4% to 16.7% (from 2011 to 2014), and CMR usage increased from 0.9% to 2.9% [ 54 ].…”

Section: Cmr Imaging Biomarkers In the Assessment Of Cardiotoxicitymentioning

confidence: 99%

Cardiovascular Magnetic Resonance Imaging in the Early Detection of Cardiotoxicity Induced by Cancer Therapies

Wei

Zhang

et al. 2022

Diagnostics

View full text Add to dashboard Cite

The significant progress in cancer treatment, including chemotherapy, immunotherapy, radiotherapy, and combination therapies, has led to higher long-term survival rates in cancer patients, while the cardiotoxicity caused by cancer treatment has become increasingly prominent. Cardiovascular magnetic resonance (CMR) is a non-invasive comprehensive imaging modality that provides not only anatomical information, but also tissue characteristics and cardiometabolic and energetic assessment, leading to its increased use in the early identification of cardiotoxicity, and is of major importance in improving the survival rate of cancer patients. This review focused on CMR techniques, including myocardial strain analysis, T1 mapping, T2 mapping, and extracellular volume fraction (ECV) calculation in the detection of early myocardial injury induced by cancer therapies. We summarized the existing studies and ongoing clinical trials using CMR for the assessment of subclinical ventricular dysfunction and myocardial changes at the tissue level. The main focus was to explore the potential of clinical and preclinical CMR techniques for continuous non-invasive monitoring of myocardial toxicity associated with cancer therapy.

show abstract

Cardiac Imaging Methods for Chemotherapy-related Cardiotoxicity Screening and Related Radiation Exposure: Current Practice and Trends

Abstract: Abstract. Background: Radiation exposure is a serious concernwith usage of serial multigated acquisition (MUGA) scans (7.8mSv/study)

Cited by 10 publications

References 17 publications

State-of-the-art modalities in cardio-oncology: insight from a nuclear medicine approach

State-of-the-art modalities in cardio-oncology: insight from a nuclear medicine approach

Herceptin-Mediated Cardiotoxicity: Assessment by Cardiovascular Magnetic Resonance

Cardiovascular Magnetic Resonance Imaging in the Early Detection of Cardiotoxicity Induced by Cancer Therapies

Contact Info

Product

Resources

About